ACS Publications. Most Trusted. Most Cited. Most Read
My Activity

Circumvention of P-GP MDR as a Function of Anthracycline Lipophilicity and Charge

View Author Information
University of Miami, School of Medicine, Dept. of Cell Biology & Anatomy, Miami, Florida 33136, University of Tennessee, College of Medicine, Dept. of Pharmacology, Memphis, Tennessee 38163, Dept. of Experimental Oncology, Hollings Cancer Center, Medical University of South Carolina, Charleston, South Carolina 29425-2850, Laboratoire de Pharmacologie Cellulaire et Moleculaire, Université Paris Sud, Faculté de Pharmacie, Chatenay-Malabry, France, and University of Texas, M. D. Anderson Cancer Center, Houston, Texas 77030
Cite this: Biochemistry 1997, 36, 9, 2679–2685
Publication Date (Web):March 4, 1997
Copyright © 1997 American Chemical Society

    Article Views





    Other access options


    From a number of studies it has been suggested that positive charge and degree of lipophilicity dictate, or at least influence, whether anthracyclines are recognized by the apparently clinical important mechanism of tumor cell resistance, i.e., P-gp-mediated multidrug resistance. Using a selected series of analogs in which lipophilicity and or positive charge are altered we find the following:  (1) Positively-charged anthracyclines as compared to their neutral counterparts are better recognized by MDR+ cells. (2) With increasing lipophilicity charge becomes less important for MDR recognition. (3) In MDR+ cells with a resistance index to Adriamycin (ADR) of 4534, as compared to an MDR− parental line, almost all of the resistance is circumvented (resistance index = 3) with an anthracycline which does not contain a protonatable nitrogen and is highly lipophilic (partition coefficient, log p = >1.99). (4) As lipophilicity is increased to log p >1.99 and nuclear binding is decreased, anthracycline localization switches from nuclear to cytoplasmic which most likely indicates a different cytotoxic target and mechanism of action. (5) Cytoplasmically localized anthracyclines appear to distribute also in mitochondria which suggests these organelles as possible new anthracycline targets. In contrast, ADR shows no mitochondrial localization. (6) Photoaffinity analysis suggests that the highly lipophilic analogs, regardless of charge, interfere with NASV-Vp binding to P-gp. This is consistent with the idea that highly lipophilic anthracyclines act as modulators of MDR which may contribute to their mechanism of overcoming this form of resistance. The possible clinical significance of these data is that highly lipophilic anthracyclines are shown to circumvent MDR which most likely reflects their ability to localize in the cytoplasm and affect targets other than nuclear DNA, i.e., mitochondria, and to act as self modulators of MDR. Thus, a new approach to circumventing MDR and other mechanisms of resistance which involve nuclear targets is the use of active anthracyclines which are highly lipophilic and localize in the cytoplasm/mitochondria.

    Read this article

    To access this article, please review the available access options below.

    Get instant access

    Purchase Access

    Read this article for 48 hours. Check out below using your ACS ID or as a guest.


    Access through Your Institution

    You may have access to this article through your institution.

    Your institution does not have access to this content. You can change your affiliated institution below.


    In papers with more than one author, the asterisk indicates the name of the author to whom inquiries about the paper should be addressed.

     University of Miami.


     University of Tennessee.

     Medical University of South Carolina.

     Université Paris Sud.


     University of Texas.

     Abstract published in Advance ACS Abstracts, February 15, 1997.

    Cited By

    This article is cited by 57 publications.

    1. Yufeng Pei, Yajun Liu, Chunyu Xie, Xinghua Zhang, Huijuan You. Detecting the Formation Kinetics of Doxorubicin-DNA Interstrand Cross-link at the Single-Molecule Level and Clinically Relevant Concentrations of Doxorubicin. Analytical Chemistry 2020, 92 (6) , 4504-4511.
    2. Erica L. Campbell, Colin K. Skepper, Kuppusamy Sankar, Katharine K. Duncan, and Dale L. Boger . Transannular Diels–Alder/1,3-Dipolar Cycloaddition Cascade of 1,3,4-Oxadiazoles: Total Synthesis of a Unique Set of Vinblastine Analogues. Organic Letters 2013, 15 (20) , 5306-5309.
    3. Timothy J. Barker, Katharine K. Duncan, Katerina Otrubova, and Dale L. Boger . Potent Vinblastine C20′ Ureas Displaying Additionally Improved Activity Against a Vinblastine-Resistant Cancer Cell Line. ACS Medicinal Chemistry Letters 2013, 4 (10) , 985-988.
    4. Erick K. Leggans, Katharine K. Duncan, Timothy J. Barker, Kristin D. Schleicher, and Dale L. Boger . A Remarkable Series of Vinblastine Analogues Displaying Enhanced Activity and an Unprecedented Tubulin Binding Steric Tolerance: C20′ Urea Derivatives. Journal of Medicinal Chemistry 2013, 56 (3) , 628-639.
    5. Erika Ferrari, Francesca Pignedoli, Carol Imbriano, Gaetano Marverti, Valentina Basile, Ettore Venturi, and Monica Saladini . Newly Synthesized Curcumin Derivatives: Crosstalk between Chemico-physical Properties and Biological Activity. Journal of Medicinal Chemistry 2011, 54 (23) , 8066-8077.
    6. Hiroaki Gotoh, Katharine K. Duncan, William M. Robertson, and Dale L. Boger . 10′-Fluorovinblastine and 10′-Fluorovincristine: Synthesis of a Key Series of Modified Vinca Alkaloids. ACS Medicinal Chemistry Letters 2011, 2 (12) , 948-952.
    7. Porino Va, Erica L. Campbell, William M. Robertson and Dale L. Boger. Total Synthesis and Evaluation of a Key Series of C5-Substituted Vinblastine Derivatives. Journal of the American Chemical Society 2010, 132 (24) , 8489-8495.
    8. David J. Burkhart,, Benjamin L. Barthel,, Glen C. Post,, Brian T. Kalet,, Jordan W. Nafie,, Richard K. Shoemaker, and, Tad H. Koch. Design, Synthesis, and Preliminary Evaluation of Doxazolidine Carbamates as Prodrugs Activated by Carboxylesterases. Journal of Medicinal Chemistry 2006, 49 (24) , 7002-7012.
    9. Glen C. Post,, Benjamin L. Barthel,, David J. Burkhart,, John R. Hagadorn, and, Tad H. Koch. Doxazolidine, a Proposed Active Metabolite of Doxorubicin That Cross-links DNA. Journal of Medicinal Chemistry 2005, 48 (24) , 7648-7657.
    10. Mounia Badis,, Iwona Tomaszkiewicz,, Jean-Pierre Joly, and, Ewa Rogalska. Enantiomeric Recognition of Amino Acids by Amphiphilic Crown Ethers in Langmuir Monolayers. Langmuir 2004, 20 (15) , 6259-6267.
    11. Patrick J. Burke and, Tad H. Koch. Design, Synthesis, and Biological Evaluation of Doxorubicin−Formaldehyde Conjugates Targeted to Breast Cancer Cells. Journal of Medicinal Chemistry 2004, 47 (5) , 1193-1206.
    12. Dylan J. Taatjes,, David J. Fenick, and, Tad H. Koch. Epidoxoform:  A Hydrolytically More Stable Anthracycline−Formaldehyde Conjugate Toxic to Resistant Tumor Cells. Journal of Medicinal Chemistry 1998, 41 (8) , 1306-1314.
    13. David J. Fenick,, Dylan J. Taatjes, and, Tad H. Koch. Doxoform and Daunoform:  Anthracycline−Formaldehyde Conjugates Toxic to Resistant Tumor Cells. Journal of Medicinal Chemistry 1997, 40 (16) , 2452-2461.
    14. Rachel M. Gillard, Jiajun Zhang, Richard Steel, Jocelyn Wang, Jessica L. Strull, Bin Cai, Nilanjana Chakraborty, Dale L. Boger. Aryl Annulation: A Powerful Simplifying Retrosynthetic Disconnection. Synthesis 2024, 56 (01) , 118-133.
    15. Alexander S. Tikhomirov, Yuri B. Sinkevich, Lyubov G. Dezhenkova, Dmitry N. Kaluzhny, Nikolay S. Ilyinsky, Valentin I. Borshchevskiy, Dominique Schols, Andrey E. Shchekotikhin. Synthesis and antitumor activity of cyclopentane-fused anthraquinone derivatives. European Journal of Medicinal Chemistry 2023, 72 , 116103.
    16. Alexander S. Tikhomirov, Vladimir B. Tsvetkov, Yulia L. Volodina, Valeria A. Litvinova, Daria V. Andreeva, Lyubov G. Dezhenkova, Dmitry N. Kaluzhny, Ivan D. Treshalin, Alexander A. Shtil, Andrey E. Shchekotikhin. Heterocyclic ring expansion yields anthraquinone derivatives potent against multidrug resistant tumor cells. Bioorganic Chemistry 2022, 127 , 105925.
    17. Preeti Kulkarni, Suraksha Kadam, Disha Sharma, Manisha Mishra, Vaidhun Bhaskar. DNA Topoisomerases: As target for anti-cancer drugs. Indian Journal of Pharmacy and Pharmacology 2022, 9 (1) , 13-17.
    18. Michalina Zaborowska, Damian Dziubak, Philippe Fontaine, Dorota Matyszewska. Influence of lipophilicity of anthracyclines on the interactions with cholesterol in the model cell membranes – Langmuir monolayer and SEIRAS studies. Colloids and Surfaces B: Biointerfaces 2022, 211 , 112297.
    19. Dorota Matyszewska, Angelika Jocek. The effect of acyl chain length and saturation on the interactions of pirarubicin with phosphatidylethanolamines in 2D model urothelial cancer cell membranes. Journal of Molecular Liquids 2021, 323 , 114633.
    20. Dorota Matyszewska, Ewa Nazaruk, Richard A. Campbell. Interactions of anticancer drugs doxorubicin and idarubicin with lipid monolayers: New insight into the composition, structure and morphology. Journal of Colloid and Interface Science 2021, 581 , 403-416.
    21. Dorota Matyszewska. The influence of charge and lipophilicity of daunorubicin and idarubicin on their penetration of model biological membranes – Langmuir monolayer and electrochemical studies. Biochimica et Biophysica Acta (BBA) - Biomembranes 2020, 1862 (2) , 183104.
    22. Karolina Kowalczyk, Andrzej Błauż, Wojciech M. Ciszewski, Anna Wieczorek, Błażej Rychlik, Damian Plażuk. Colchicine metallocenyl bioconjugates showing high antiproliferative activities against cancer cell lines. Dalton Transactions 2017, 46 (48) , 17041-17052.
    23. Stefania Nobili, Ida Landini, Teresita Mazzei, Enrico Mini. Overcoming tumor multidrug resistance using drugs able to evade P‐glycoprotein or to exploit its expression. Medicinal Research Reviews 2012, 32 (6) , 1220-1262.
    24. Ye Su, Xin Cheng, Yaohong Tan, Yunhui Hu, Yuan Zhou, Juanni Liu, Yuanfu Xu, Yinliang Xie, Caiyun Wang, Yingdai Gao, Jianxiang Wang, Tao Cheng, Chunzheng Yang, Dongsheng Xiong, Hua Miao, . Synthesis of a Dual Functional Anti-MDR Tumor Agent PH II-7 with Elucidations of Anti-Tumor Effects and Mechanisms. PLoS ONE 2012, 7 (3) , e32782.
    25. Xiao-Bing Xiong, Arash Falamarzian, Shyam M Garg, Afsaneh Lavasanifar. Engineering of amphiphilic block copolymers for polymeric micellar drug and gene delivery. Journal of Controlled Release 2011, 155 (2) , 248-261.
    26. Cyril Rauch. The “Multi” of Drug Resistance Explained by Oscillating Drug Transporters, Drug–Membrane Physical Interactions and Spatial Dimensionality. Cell Biochemistry and Biophysics 2011, 61 (1) , 103-113.
    27. Xiao-Bing Xiong, Afsaneh Lavasanifar. Amphiphilic Block Copolymer Based Nanocarriers for Drug and Gene Delivery. 2011, 251-289.
    28. Annie Tam, Hiroaki Gotoh, William M. Robertson, Dale L. Boger. Catharanthine C16 substituent effects on the biomimetic coupling with vindoline: Preparation and evaluation of a key series of vinblastine analogues. Bioorganic & Medicinal Chemistry Letters 2010, 20 (22) , 6408-6410.
    29. Xiao-Bing Xiong, Zengshuan Ma, Raymond Lai, Afsaneh Lavasanifar. The therapeutic response to multifunctional polymeric nano-conjugates in the targeted cellular and subcellular delivery of doxorubicin. Biomaterials 2010, 31 (4) , 757-768.
    30. Hamid Morjani, Claudie Madoulet. Reversal Agents for P‐Glycoprotein‐Mediated Multidrug Resistance. 2009, 239-259.
    31. Metin Kurtoglu, Theodore J. Lampidis. From delocalized lipophilic cations to hypoxia: Blocking tumor cell mitochondrial function leads to therapeutic gain with glycolytic inhibitors. Molecular Nutrition & Food Research 2009, 53 (1) , 68-75.
    32. Gaetano Marverti, Matteo Cusumano, Alessio Ligabue, Maria Letizia Di Pietro, Pasquale Antonio Vainiglia, Angela Ferrari, Margherita Bergomi, Maria Stella Moruzzi, Chiara Frassineti. Studies on the anti-proliferative effects of novel DNA-intercalating bipyridyl–thiourea–Pt(II) complexes against cisplatin-sensitive and -resistant human ovarian cancer cells. Journal of Inorganic Biochemistry 2008, 102 (4) , 699-712.
    33. Alla Korynevska, Petra Heffeter, Bohdan Matselyukh, Leonilla Elbling, Michael Micksche, Rostyslav Stoika, Walter Berger. Mechanisms underlying the anticancer activities of the angucycline landomycin E. Biochemical Pharmacology 2007, 74 (12) , 1713-1726.
    34. Sylvia Mansilla, Marta Rojas, Marc Bataller, Waldemar Priebe, José Portugal. Circumvention of the multidrug-resistance protein (MRP-1) by an antitumor drug through specific inhibition of gene transcription in breast tumor cells. Biochemical Pharmacology 2007, 73 (7) , 934-942.
    35. Gergely Szakács, Jill K. Paterson, Joseph A. Ludwig, Catherine Booth-Genthe, Michael M. Gottesman. Targeting multidrug resistance in cancer. Nature Reviews Drug Discovery 2006, 5 (3) , 219-234.
    36. David J. Burkhart, Brian T. Kalet, Michael P. Coleman, Glen C. Post, Tad H. Koch. Doxorubicin-formaldehyde conjugates targeting αvβ3 integrin. Molecular Cancer Therapeutics 2004, 3 (12) , 1593-1604.
    37. Alex V. Trevino, Barbara A. Woynarowska, Terence S. Herman, Waldemar Priebe, Jan M. Woynarowski. Enhanced topoisomerase II targeting by annamycin and related 4-demethoxy anthracycline analogues. Molecular Cancer Therapeutics 2004, 3 (11) , 1403-1410.
    38. Giorgio Minotti, Pierantonio Menna, Emanuela Salvatorelli, Gaetano Cairo, Luca Gianni. Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity. Pharmacological Reviews 2004, 56 (2) , 185-229.
    39. L Gate, P Couvreur, G Nguyen-Ba, H Tapiero. N-methylation of anthracyclines modulates their cytotoxicity and pharmacokinetic in wild type and multidrug resistant cells. Biomedicine & Pharmacotherapy 2003, 57 (7) , 301-308.
    40. Ross A Davey, Mary W Davey, Karen V Cullen, Xanthe E Wells, Craig L Francis, Hua‐Ming Williams, Qi Yang, Minoo J Moghaddam, Fred Widmer, Robert G Whittaker. The use of Tris‐Lipidation to modify drug cytotoxicity in multidrug resistant cells expressing P‐glycoprotein or MRP1. British Journal of Pharmacology 2002, 137 (8) , 1280-1286.
    41. Kazuto Yasuda, Lu-bin Lan, Dominique Sanglard, Katryn Furuya, John D. Schuetz, Erin G. Schuetz. Interaction of Cytochrome P450 3A Inhibitors with P-Glycoprotein. Journal of Pharmacology and Experimental Therapeutics 2002, 303 (1) , 323-332.
    42. Kai-Ming Chou, A.Paul Krapcho, David Horn, Miles Hacker. Characterization of anthracenediones and their photoaffinity analogs. Biochemical Pharmacology 2002, 63 (6) , 1143-1147.
    43. Olga V. Leontieva, Maria N. Preobrazhenskaya, Ralph J. Bernacki. Partial Circumvention of P-Glycoprotein-Mediated Multidrug Resistance by Doxorubicin-14-O-Hemiadipate. Investigational New Drugs 2002, 20 (1) , 35-48.
    44. Kai-Ming Chou, A. Paul Krapcho, Miles P. Hacker. Impact of the basic amine on the biological activity and intracellular distribution of an aza-anthrapyrazole: BBR 342244Abbreviations: MDR, multidrug resistance; NHS-ASA, N-hydroxysuccinimidyl-4-azidosalicylic acid; SRB, sulforhodomine B; and P-gp, P-glycoprotein.. Biochemical Pharmacology 2001, 62 (10) , 1337-1343.
    45. Z. Topcu. DNA topoisomerases as targets for anticancer drugs. Journal of Clinical Pharmacy and Therapeutics 2001, 26 (6) , 405-416.
    46. Noriko Uchiyama‐Kokubu, Toru Watanabe, Dalia Cohen. Intracellular Levels of Two Cyclosporin Derivatives Valspodar (PSC 833) and Cyclosporin A Closely Associated with Multidrug Resistance‐modulating Activity in Sublines of Human Colorectal Adenocarcinoma HCT‐15. Japanese Journal of Cancer Research 2001, 92 (10) , 1116-1126.
    47. Ki H Kim. 3D-QSAR Analysis of 2,4,5- and 2,3,4,5-substituted imidazoles as potent and nontoxic modulators of P-glycoprotein mediated MDR. Bioorganic & Medicinal Chemistry 2001, 9 (6) , 1517-1523.
    48. Liliana Manciu, Xiu-Bao Chang, John R. Riordan, Frédéric Buyse, Jean Marie Ruysschaert. Nucleotide‐induced conformational changes in the human multidrug resistance protein MRP1 are related to the capacity of chemotherapeutic drugs to accumulate or not in resistant cells. FEBS Letters 2001, 493 (1) , 31-35.
    49. Jacques Ferté. Analysis of the tangled relationships between P‐glycoprotein‐mediated multidrug resistance and the lipid phase of the cell membrane. European Journal of Biochemistry 2000, 267 (2) , 277-294.
    50. Ahmad R. Safa. Photoaffinity analogs for multidrug resistance-related transporters and their use in identifying chemosensitizers. Drug Resistance Updates 1999, 2 (6) , 371-381.
    51. Gunnar Liminga, Bertil Jonsson, Peter Nygren, Rolf Larsson. On the mechanism underlying calcein-induced cytotoxicity. European Journal of Pharmacology 1999, 383 (3) , 321-329.
    52. Dick J. Roovers, Marja van Vliet, Andries C. Bloem, Henk M. Lokhorst. Idarubicin overcomes P-glycoprotein-related multidrug resistance: comparison with doxorubicin and daunorubicin in human multiple myeloma cell lines. Leukemia Research 1999, 23 (6) , 539-548.
    53. Barbra H. Stewart, O. Helen Chan. Use of immobilized artificial membrane chromatography for drug transport applications††Abbreviations: blood-brain barrier, BBB; bovine brain microvessel endothelial cells, BBMEC; calculated log distribution coefficient (Pallas, CompuDrug, Budapest, Hungary), ClogD; calculated log partition coefficient, ClogP; capacity factor on an IAM column, k¢IAM; capacity factor on a reversed-phase column, k¢w; log distribution coefficient, log D; immobilized artificial membrane, IAM; nonsteroidal antiinflammatory, NSAID; octadecylsilicate, ODS; log octanol:water intrinsic partition coefficient, log P; phosphate-buffered saline, PBS; phosphatidylcholine, PC.. Journal of Pharmaceutical Sciences 1998, 87 (12) , 1471-1478.
    54. Erland J.F Demant, Ellen Friche. Kinetics of anthracycline accumulation in multidrug-resistant tumor cells: relationship to drug lipophilicity and serum albumin binding. Biochemical Pharmacology 1998, 56 (9) , 1209-1217.
    55. J.L. Teillaud, N Gruel, J Moncuit, Z Mishal, W.H. Fridman, T.J. Lampidis, H Tapiero. Structurally different anthracyclines provoke different effects on cell cycle and tumor B cell differentiation. Biomedicine & Pharmacotherapy 1998, 52 (6) , 282-290.
    56. Toru Watanabe, Noriko Kokubu, Steven B. Charnick, Mikihiko Naito, Takashi Tsuruo, Dalia Cohen. Interaction of cyclosporin derivatives with the ATPase activity of human P‐glycoprotein. British Journal of Pharmacology 1997, 122 (2) , 241-248.
    57. Gera D. Eytan, Ronit Regev, Galit Oren, Charles D. Hurwitz, Yehuda G. Assaraf. Efficiency of P‐glycoprotein–Mediated Exclusion of Rhodamine Dyes from Multidrug‐Resistant Cells is Determined by their Passive Transmembrane Movement Rate. European Journal of Biochemistry 1997, 248 (1) , 104-112.

    Pair your accounts.

    Export articles to Mendeley

    Get article recommendations from ACS based on references in your Mendeley library.

    Pair your accounts.

    Export articles to Mendeley

    Get article recommendations from ACS based on references in your Mendeley library.

    You’ve supercharged your research process with ACS and Mendeley!

    STEP 1:
    Click to create an ACS ID

    Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.

    Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.

    Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.

    Your Mendeley pairing has expired. Please reconnect